PZ-2891 was initially designed as a nonselective modulator of PANK, the rate-limiting enzyme for CoA biosynthesis, while the RT–qPCR and WB results revealed that it more strongly modulated PANK2 than other subtypes in AD pathology. Here, PANK2 is linked to Alzheimer disease.